{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:33:20Z","timestamp":1792100000540,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018720","name":"Advanced Accelerator Applications","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018720","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Resection of non-functioning pancreatic neuroendocrine tumours (NF-PanNETs) is curative in most patients. The potential benefits of neoadjuvant treatments have, however, never been explored. The primary aim of this study was to evaluate the safety of neoadjuvant 177Lu-labelled DOTA0-octreotate (177Lu-DOTATATE) followed by surgery in patients with NF-PanNETs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>NEOLUPANET was a multicentre, single-arm, phase II trial of patients with sporadic, resectable or potentially resectable NF-PanNETs at high-risk of recurrence; those with positive 68Ga-labelled DOTA PET were eligible. All patients were candidates for neoadjuvant 177Lu-DOTATATE followed by surgery. A sample size of 30 patients was calculated to test postoperative complication rates against predefined cut-offs. The primary endpoint was safety, reflected by postoperative morbidity and mortality within 90 days. Secondary endpoints included rate of objective radiological response and quality of life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From March 2020 to February 2023, 31 patients were enrolled, of whom 26 completed 4 cycles of 177Lu-DOTATATE. A partial radiological response was observed in 18 of 31 patients, and 13 patients had stable disease. Disease progression was not observed. Twenty-four R0 resections and 4 R1 resections were performed in 29 patients who underwent surgery. One tumour was unresectable owing to vascular involvement. There was no postoperative death. Postoperative complications occurred in 21 of 29 patients. Severe complications were observed in seven patients. Quality of life remained stable after 177Lu-DOTATATE and decreased after surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Neoadjuvant treatment with 177Lu-DOTATATE is safe and effective for patients with NF-PanNETs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znae178","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T20:08:19Z","timestamp":1725048499000},"source":"Crossref","is-referenced-by-count":50,"title":["Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study"],"prefix":"10.1093","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6170","authenticated-orcid":false,"given":"Stefano","family":"Partelli","sequence":"first","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Pancreas Translational and Clinical Research Centre, Pancreatic and Transplant Surgery Unit, IRCCS San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Landoni","sequence":"additional","affiliation":[{"name":"General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona Hospital Trust , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Bartolomei","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara , Ferrara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zerbi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]},{"name":"Pancreatic Surgery Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Grana","sequence":"additional","affiliation":[{"name":"Radiometabolic Therapy Unit, Division of Nuclear Medicine, IRCCS European Institute of Oncology , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Boggi","sequence":"additional","affiliation":[{"name":"Division of General and Transplant Surgery, University of Pisa , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Butturini","sequence":"additional","affiliation":[{"name":"Department of Surgery, Pederzoli Hospital , Peschiera del Garda ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Casadei","sequence":"additional","affiliation":[{"name":"Division of Pancreatic Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]},{"name":"Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvia","sequence":"additional","affiliation":[{"name":"General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona Hospital Trust , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Pancreas Translational and Clinical Research Centre, Pancreatic and Transplant Surgery Unit, IRCCS San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"2024093003454645500_znae178-B1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2024093003454645500_znae178-B2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024093003454645500_znae178-B3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00259-020-04873-0","article-title":"177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study","volume":"48","author":"Paganelli","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024093003454645500_znae178-B4","doi-asserted-by":"crossref","first-page":"e220290","DOI":"10.1001\/jamanetworkopen.2022.0290","article-title":"Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors","volume":"5","author":"Pusceddu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024093003454645500_znae178-B5","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2024093003454645500_znae178-B6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024093003454645500_znae178-B7","doi-asserted-by":"crossref","first-page":"e212274","DOI":"10.1001\/jamanetworkopen.2021.2274","article-title":"Laboratory, clinical, and survival outcomes associated with peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Kipnis","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024093003454645500_znae178-B8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/SLA.0000000000002594","article-title":"The evolution of surgical strategies for pancreatic neuroendocrine tumors (Pan-NENs)","volume":"269","author":"Landoni","year":"2019","journal-title":"Ann Surg"},{"key":"2024093003454645500_znae178-B9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/SLA.0000000000002123","article-title":"A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors","volume":"267","author":"Gen\u00e7","year":"2018","journal-title":"Ann Surg"},{"key":"2024093003454645500_znae178-B10","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1245\/s10434-018-6518-2","article-title":"Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67","volume":"25","author":"Gen\u00e7","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2024093003454645500_znae178-B11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40618-021-01705-2","article-title":"Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis","volume":"45","author":"Andreasi","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"2024093003454645500_znae178-B12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/SLA.0000000000003461","article-title":"A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients","volume":"270","author":"Zaidi","year":"2019","journal-title":"Ann Surg"},{"key":"2024093003454645500_znae178-B13","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1245\/s10434-023-13117-y","article-title":"Prognostic significance and predictors of nodal recurrence after surgery for non-functioning pancreatic neuroendocrine tumors","volume":"30","author":"Partelli","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2024093003454645500_znae178-B14","doi-asserted-by":"crossref","first-page":"687925","DOI":"10.3389\/fonc.2021.687925","article-title":"Value of peptide receptor radionuclide therapy as neoadjuvant treatment in the management of primary inoperable neuroendocrine tumors","volume":"11","author":"Opali\u0144ska","year":"2021","journal-title":"Front Oncol"},{"key":"2024093003454645500_znae178-B15","doi-asserted-by":"publisher","article-title":"Neoadjuvant on the gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","author":"Chen","DOI":"10.21203\/rs.3.rs-208725\/v1"},{"key":"2024093003454645500_znae178-B16","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0, Tyr3]octreotate","volume":"56","author":"van Vliet","year":"2015","journal-title":"J Nucl Med"},{"key":"2024093003454645500_znae178-B17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000501126","article-title":"The role of perioperative systemic therapy in localized pancreatic neuroendocrine neoplasms","volume":"110","author":"Xie","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2024093003454645500_znae178-B18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.surg.2017.11.007","article-title":"Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms","volume":"163","author":"Partelli","year":"2018","journal-title":"Surgery"},{"key":"2024093003454645500_znae178-B19","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"2024093003454645500_znae178-B20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2024093003454645500_znae178-B21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","article-title":"The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after","volume":"161","author":"Bassi","year":"2017","journal-title":"Surgery"},{"key":"2024093003454645500_znae178-B22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.surg.2007.05.005","article-title":"Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"142","author":"Wente","year":"2007","journal-title":"Surgery"},{"key":"2024093003454645500_znae178-B23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2024093003454645500_znae178-B24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"2024093003454645500_znae178-B25","volume-title":"TNM Classification of Malignant Tumours","author":"Brierly","year":"2017","edition":"(8th edn)"},{"key":"2024093003454645500_znae178-B26","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2017","edition":"(4th edn)"},{"key":"2024093003454645500_znae178-B27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2024093003454645500_znae178-B28","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/bjs\/znac267","article-title":"Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial","volume":"109","author":"Partelli","year":"2022","journal-title":"Br J Surg"},{"key":"2024093003454645500_znae178-B29","doi-asserted-by":"crossref","first-page":"e2024318","DOI":"10.1001\/jamanetworkopen.2020.24318","article-title":"Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors","volume":"3","author":"Titan","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2024093003454645500_znae178-B30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000494258","article-title":"Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms","volume":"108","author":"Jensen","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2024093003454645500_znae178-B31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00423-020-01869-0","article-title":"Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias","volume":"405","author":"Albers","year":"2020","journal-title":"Langenbecks Arch Surg"},{"key":"2024093003454645500_znae178-B32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MPA.0000000000001273","article-title":"Risk and predictors of postoperative morbidity and mortality after pancreaticoduodenectomy for pancreatic neuroendocrine neoplasms: a comparative study with pancreatic ductal adenocarcinoma","volume":"48","author":"Partelli","year":"2019","journal-title":"Pancreas"},{"key":"2024093003454645500_znae178-B33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hpb.12319","article-title":"Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions","volume":"17","author":"Atema","year":"2015","journal-title":"HPB (Oxford)"},{"key":"2024093003454645500_znae178-B34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.amjsurg.2022.07.007","article-title":"Predictors of post-operative pancreatic fistula formation in pancreatic neuroendocrine tumors: a national surgical quality improvement program analysis","volume":"224","author":"Hedges","year":"2022","journal-title":"Am J Surg"},{"key":"2024093003454645500_znae178-B35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12022-020-09623-4","article-title":"Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT)","volume":"31","author":"Schiavo Lena","year":"2020","journal-title":"Endocr Pathol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/9\/znae178\/59328577\/znae178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/9\/znae178\/59328577\/znae178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T03:46:03Z","timestamp":1727667963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znae178\/7745995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8,30]]},"published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znae178","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,30]]},"article-number":"znae178"}}